focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I originally invested in NSCI because of Glycotest which, if successful will be real money maker. In the annual report they have given a lot more detail about it's current status.
Vortex bio also has great potential, just look at AGL!
Wilco, Below are a couple of examples that I have seen which give you a feel for the scope.
https://www.pbctoday.co.uk/news/planning-construction-news/social-housing-disruptors-framework/105366/
https://www.housing-technology.com/q-bot-underfloor-robots-at-plus-dane/
From what I have seen, at the beginning Q-bot was mainly doing private one off household type jobs. Now they involved in framework agreements, housing authorities etc.
Anyone the possible size of the addressable market for Q-Bot?
Not massively well versed and primarily in NSCI for the PDSB stake but sounds quite an exciting business
>> This round, which comprised conversion of £762,000 of loan notes (of which £500,000 was provided by NetScientific as announced on 21 December 2021) and £900,000 of new equity, results in the direct equity holding in Q-Bot by NetScientific increasing from 18.3% to 20.6%, in addition to EMVC's Capital Under Advisory representing 16.7%. NetScientific's 20.6% Q-Bot direct stake is valued at £2.77m based on this funding round- a gain of approximately £1.45m in less than one year.
That (paper) gain equates to around a 6p gain on the current share price. Not bad!
https://www.biospace.com/article/circulating-tumor-cells-market-size-to-surpass-us-20-3-bn-by-2030/
"Advancements in technologies such as immunofluorescence, NGS, FISH, and qPCR are anticipated to drive the clinical utility of these cells, and thus accelerating revenue growth for CTC analyses. Several companies are investing in the development of products that help in CTC analysis and downstream assays. For instance, Vortex Biosciences offers various CTC analysis products, including immunofluorescence, cytopathology, cytogenetics (FISH), cell culture, and genomics."
Fantastic RNS
Two days of approximately four times average volume and heavy fall in sp
Volume in excess of 1.2 million shares traded each day.
Today announcement of fast track for PDS0101 in combination with Keytruda
https://newsfilter.io/articles/pds-biotechnology-granted-fda-fast-track-designation-for-lead-candidate-pds0101-0f6d394fc139b59742198fe46f232192
Already almost 14 million shares traded in the first hour and a half. SP recovering.
Thank you both, very inciteful!
Been looking into this and what I can gleam from it is it's likely been caused by further reaction to the refractory patients in the triple-combo trial announced end of last week.
Firstly concerns seem to have arisen from the falling OR compared to the 2021 data. This can be explained by the testing of the lower 8mcg M9241 dosage which achieved an OR of just 7%. The lower dosage was only implemented into the trial towards the halfway stage and this may have lead to further concerns that this was to limit an increasing rate of adverse events (AE's) from patients receiving the original higher 16mcg dosage.
However, this doesn't appear to be a valid concern. Frank Bedu-Addo has already stated the intention of using higher and lower dosages to prove the impact of the M9241 element of the triple combo which should make FDA approval and commercialisation quicker in the future. This was always part of the plan and I'm hopeful this will be clarified next week.
Adding to that, expansion into Europe is another step in the right direction.
As I understand it the trial consists of patients at stage 5 cancer of the head & neck with an average four month
life expectancy. Latest update on 26th May shows 89% of patients alive at median 9 months, does not look bad to me.
I suspect with 19 patients it is challenging statistically, hence the expansion of the trial to the UK.
The larger the cohort the more accurately you can assess the benefit or non benefit of the treatment.
Having followed PDSB for a while it seems obvious to me the market for this small stock (for US market) is rigged.
We may see one or more institutions have sold heavily.
I have a theory - which coud be wishful thinking on my part that this is part of Merk's opening move, unsettling traders, small investors by exploiting a small difference since the last update relating to patients on the lowest dose.
That whilst we see heavy selling - Merk are already accumulating stock at very low prices.
The markets don't seem 8mpressed with it, down 23% today! Was there any bad news in there?
Versamune-002 trial is being extended to UK
https://newsfilter.io/a/9d5ecc06bf322e3d6d743878924cc00f
In addition to PDS news - from ProAxsis company page on LinkedIn -
Exciting news!! ProAxsis Ltd. is officially the Best Established Small Business WINNER of the 2022 Belfast Telegraph Business Awards, which took place last night.
This is such a great achievement for our expanding team, showing we have demonstrated innovation, growth and successfully overcome challenges following a tough time caused by the Pandemic.
Oh wow, somehow missed that Versamune-002 abstract also released! Considering these are patients who really have no options left, survival rates are again excellent. OR of 41.2% double the current CPI treatment, only 4 of the 17 had no impact from the treatment and again that could change prior to the full data presentation. More excellent news...
Strange time of day for an RNS but an excellent one nonetheless
Survival rates are really excellent for the inhibitor refractory patients, usually live 3-4 months, 77% alive after 12 months. ORR pretty decent but very possibly will improve when the data is presented at ASCO as this will include the period up to May, this extract is to March only.
On the whole PDSB is a real gem and the scale of potential applications for Versamune is genuinely mindblowing should it ever reach commercialisation. The fact its up on the day of a clinical data announcement says A LOT on the Nasdaq. If a company can stay out of the red on results day it's generally known to have been very good data.
Positive results from phase 2 clinical trial
Good news from PDSB to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 3-7, 2022 in Chicago
https://www.sec.gov/Archives/edgar/data/1472091/000114036122020836/brhc10038208_ex99-1.htm
£77k bought £18k sold. Can't carry on like this much longer without another good tick up
https://twitter.com/NetScientific/status/1527561814841643008?t=JInP_Gf0H0AIF9yeQ659NA&s=19
Nothing new but at least they're out there doing PR
Always followed and invested in this company, but very long term for me, you can see the progress happening on multiple fronts, and I trust and respect the work the CEO is doing.
Good news, Hope Ed can help execute some of NSCI's plans.
"to prepare and deliver exit and liquidity events for them, as part of the Company's planned strategy to realise shareholder value and returns."